ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit ...

TIBSOVO is a targeted therapy that works against an abnormal protein created by a mutation in the IDH1 gene. This abnormal ...

In updated 2025 American Society of Hematology guidelines, recommendations are presented for the management of newly ...

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led ...

Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise ...

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction ...